DDIT3 and diffuse large B-cell lymphoma: Building upon the previous work [4], the objective of this analysis was to examine the association between changes in PROs over time and PFS and OS in patients with DLBCL who were newly treated with obinutuzumab (G) in combination with CHOP (G-CHOP) or rituximab (R) with CHOP (R-CHOP), in the GOYA Phase 3 trial.